search icon
eton-img

Eton Pharmaceuticals Inc, Common Stock

ETON

NMQ

$19

+$0.08

(0.42%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$543.06M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
264.54K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.18 L
$21.48 H
$19

About Eton Pharmaceuticals Inc, Common Stock

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameETONSectorS&P500
1-Week Return-6.57%1.39%1.18%
1-Month Return14.74%-4.97%6.44%
3-Month Return20.51%-11.13%-0.73%
6-Month Return39.84%-10.21%-2.01%
1-Year Return411.35%-6.5%12.12%
3-Year Return522.37%0.1%42.84%
5-Year Return311.3%28.49%93.86%
10-Year Return202.72%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue39.00K21.83M21.25M31.64M39.01M[{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":55.96,"profit":true},{"date":"2022-12-31","value":54.47,"profit":true},{"date":"2023-12-31","value":81.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue286.00K2.62M6.93M10.58M15.60M[{"date":"2020-12-31","value":1.83,"profit":true},{"date":"2021-12-31","value":16.81,"profit":true},{"date":"2022-12-31","value":44.44,"profit":true},{"date":"2023-12-31","value":67.83,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(247.00K)19.21M14.32M21.06M23.41M[{"date":"2020-12-31","value":-1.06,"profit":false},{"date":"2021-12-31","value":82.05,"profit":true},{"date":"2022-12-31","value":61.16,"profit":true},{"date":"2023-12-31","value":89.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(633.33%)87.99%67.38%66.56%60.01%[{"date":"2020-12-31","value":-719.82,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.58,"profit":true},{"date":"2023-12-31","value":75.65,"profit":true},{"date":"2024-12-31","value":68.21,"profit":true}]
Operating Expenses26.86M20.70M22.58M22.25M26.01M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.07,"profit":true},{"date":"2022-12-31","value":84.05,"profit":true},{"date":"2023-12-31","value":82.84,"profit":true},{"date":"2024-12-31","value":96.81,"profit":true}]
Operating Income(27.11M)(1.50M)(8.26M)(1.19M)(2.60M)[{"date":"2020-12-31","value":-2711100000,"profit":false},{"date":"2021-12-31","value":-149500000,"profit":false},{"date":"2022-12-31","value":-826000000,"profit":false},{"date":"2023-12-31","value":-119200000,"profit":false},{"date":"2024-12-31","value":-259700000,"profit":false}]
Total Non-Operating Income/Expense(1.72M)(1.47M)(1.52M)1.01M(2.42M)[{"date":"2020-12-31","value":-170.78,"profit":false},{"date":"2021-12-31","value":-145.73,"profit":false},{"date":"2022-12-31","value":-151.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-240.76,"profit":false}]
Pre-Tax Income(27.97M)(1.96M)(9.02M)(689.00K)(3.81M)[{"date":"2020-12-31","value":-2797000000,"profit":false},{"date":"2021-12-31","value":-195500000,"profit":false},{"date":"2022-12-31","value":-902100000,"profit":false},{"date":"2023-12-31","value":-68900000,"profit":false},{"date":"2024-12-31","value":-380800000,"profit":false}]
Income Taxes859.00K1.01M761.00K247.00K15.00K[{"date":"2020-12-31","value":85.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.65,"profit":true},{"date":"2023-12-31","value":24.55,"profit":true},{"date":"2024-12-31","value":1.49,"profit":true}]
Income After Taxes(28.83M)(2.96M)(9.78M)(936.00K)(3.82M)[{"date":"2020-12-31","value":-2882900000,"profit":false},{"date":"2021-12-31","value":-296100000,"profit":false},{"date":"2022-12-31","value":-978200000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false},{"date":"2024-12-31","value":-382300000,"profit":false}]
Income From Continuous Operations(27.97M)(1.96M)(9.02M)(936.00K)(3.82M)[{"date":"2020-12-31","value":-2797000000,"profit":false},{"date":"2021-12-31","value":-195500000,"profit":false},{"date":"2022-12-31","value":-902100000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false},{"date":"2024-12-31","value":-382300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(28.83M)(2.96M)(9.78M)(936.00K)(3.82M)[{"date":"2020-12-31","value":-2882900000,"profit":false},{"date":"2021-12-31","value":-296100000,"profit":false},{"date":"2022-12-31","value":-978200000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false},{"date":"2024-12-31","value":-382300000,"profit":false}]
EPS (Diluted)(1.36)(0.11)(0.35)(0.06)(0.16)[{"date":"2020-12-31","value":-136,"profit":false},{"date":"2021-12-31","value":-11,"profit":false},{"date":"2022-12-31","value":-35,"profit":false},{"date":"2023-12-31","value":-6,"profit":false},{"date":"2024-12-31","value":-16,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ETON
Cash Ratio 0.69
Current Ratio 1.97
Quick Ratio 1.43

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ETON
ROA (LTM) -2.02%
ROE (LTM) -22.95%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ETON
Debt Ratio Lower is generally better. Negative is bad. 0.71
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.29

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ETON
Trailing PE NM
Forward PE 72.99
P/S (TTM) 11.14
P/B 20.75
Price/FCF 258
EV/R 10.76
EV/Ebitda 51.26

FAQs

What is Eton Pharmaceuticals Inc share price today?

Eton Pharmaceuticals Inc (ETON) share price today is $19

Can Indians buy Eton Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Eton Pharmaceuticals Inc (ETON) on Vested. To buy Eton Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ETON stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Eton Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Eton Pharmaceuticals Inc (ETON) via the Vested app. You can start investing in Eton Pharmaceuticals Inc (ETON) with a minimum investment of $1.

How to invest in Eton Pharmaceuticals Inc shares from India?

You can invest in shares of Eton Pharmaceuticals Inc (ETON) via Vested in three simple steps:

  • Click on Sign Up or Invest in ETON stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Eton Pharmaceuticals Inc shares
What is Eton Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Eton Pharmaceuticals Inc (ETON) is $21.48. The 52-week low price of Eton Pharmaceuticals Inc (ETON) is $3.18.

What is Eton Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Eton Pharmaceuticals Inc (ETON) is 20.75

What is the Market Cap of Eton Pharmaceuticals Inc?

The market capitalization of Eton Pharmaceuticals Inc (ETON) is $543.06M

What is Eton Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Eton Pharmaceuticals Inc is ETON

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top